Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 8 studies | 22% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3633.10 | 1445 / 1445 | 100% | 73.27 | 183 / 183 |
ovary | 100% | 5191.99 | 180 / 180 | 100% | 93.87 | 430 / 430 |
pancreas | 100% | 1907.44 | 328 / 328 | 100% | 56.02 | 178 / 178 |
skin | 100% | 3672.35 | 1809 / 1809 | 100% | 78.83 | 472 / 472 |
stomach | 100% | 2543.69 | 359 / 359 | 100% | 68.68 | 286 / 286 |
thymus | 100% | 4503.96 | 653 / 653 | 100% | 78.36 | 605 / 605 |
uterus | 100% | 5799.48 | 170 / 170 | 100% | 67.24 | 458 / 459 |
lung | 100% | 3818.81 | 578 / 578 | 100% | 56.58 | 1152 / 1155 |
brain | 100% | 2564.23 | 2633 / 2642 | 100% | 76.90 | 705 / 705 |
intestine | 100% | 3584.08 | 966 / 966 | 100% | 64.36 | 525 / 527 |
prostate | 100% | 3571.21 | 245 / 245 | 100% | 47.62 | 500 / 502 |
kidney | 100% | 2666.79 | 89 / 89 | 99% | 50.13 | 896 / 901 |
breast | 100% | 3959.44 | 459 / 459 | 99% | 59.00 | 1111 / 1118 |
adrenal gland | 100% | 3089.84 | 258 / 258 | 99% | 55.06 | 228 / 230 |
bladder | 100% | 3744.43 | 21 / 21 | 99% | 55.97 | 498 / 504 |
liver | 100% | 1181.18 | 225 / 226 | 99% | 29.90 | 401 / 406 |
adipose | 100% | 3470.16 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4205.10 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 79.91 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 58.63 | 29 / 29 |
muscle | 100% | 3131.26 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 4301.93 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 58.53 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 16.75 | 1 / 1 |
heart | 99% | 2379.07 | 856 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 3951.96 | 922 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006397 | Biological process | mRNA processing |
GO_0032259 | Biological process | methylation |
GO_0017148 | Biological process | negative regulation of translation |
GO_0045727 | Biological process | positive regulation of translation |
GO_0006417 | Biological process | regulation of translation |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0015630 | Cellular component | microtubule cytoskeleton |
GO_0045171 | Cellular component | intercellular bridge |
GO_0099122 | Molecular function | RNA polymerase II C-terminal domain binding |
GO_1904047 | Molecular function | S-adenosyl-L-methionine binding |
GO_1990269 | Molecular function | RNA polymerase II C-terminal domain phosphoserine binding |
GO_0016422 | Molecular function | mRNA (2'-O-methyladenosine-N6-)-methyltransferase activity |
Gene name | PCIF1 |
Protein name | Phosphorylated CTD interacting factor 1 mRNA (2'-O-methyladenosine-N(6)-)-methyltransferase (EC 2.1.1.62) (Cap-specific adenosine methyltransferase) (CAPAM) (hCAPAM) (Phosphorylated CTD-interacting factor 1) (hPCIF1) (Protein phosphatase 1 regulatory subunit 121) |
Synonyms | CAPAM C20orf67 PPP1R121 |
Description | FUNCTION: Cap-specific adenosine methyltransferase that catalyzes formation of N(6),2'-O-dimethyladenosine cap (m6A(m)) by methylating the adenosine at the second transcribed position of capped mRNAs . Recruited to the early elongation complex of RNA polymerase II (RNAPII) via interaction with POLR2A and mediates formation of m6A(m) co-transcriptionally . . |
Accessions | ENST00000479348.2 Q9H4Z3 ENST00000372409.8 A0A087WWZ2 |